Home › Trials › NCT05685433

Evaluation of eCoin for treating urgency urinary incontinence

A Real World Study of eCoin for Urgency Urinary Incontinence: Post Approval Evaluation (RECIPE)

Not applicable Interventional Valencia Technologies Corporation · NCT05685433

This study is testing whether an implanted device called eCoin can help people with urgency urinary incontinence feel better over the long term.

Quick facts

PhaseNot applicable
Study typeInterventional
Enrollment200 (estimated)
Ages18 Years and up
SexAll
SponsorValencia Technologies Corporation Industry-sponsored
Locations22 sites (Homewood, Alabama and 21 other locations)
Trial IDNCT05685433 on ClinicalTrials.gov

What this trial studies

This prospective, multicenter, single-arm study aims to assess the long-term safety and effectiveness of the eCoin® implanted tibial nerve stimulator in patients with urgency urinary incontinence (UUI). Participants will be implanted with the device and will complete voiding diaries and questionnaires over a follow-up period of up to five years. The study seeks to gather real-world data on the device's performance and its impact on patients' quality of life.

Who should consider this trial

Good fit: Ideal candidates include men and women over 18 years old diagnosed with overactive bladder and experiencing urgency urinary incontinence.

Not a fit: Patients currently on pharmacological treatments for overactive bladder or those who have not responded to previous therapies may not benefit from this study.

Why it matters

Potential benefit: If successful, this study could provide a new effective treatment option for patients suffering from urgency urinary incontinence.

How similar studies have performed: Other studies have shown positive outcomes with similar tibial nerve stimulation approaches, indicating potential for success in this evaluation.

Eligibility criteria

Show full inclusion / exclusion criteria 
Inclusion Criteria:

* Women and men above 18 years old with gender percentages reflective of disease prevalence in the U.S. population
* Individual with diagnosis of overactive bladder with urgency urinary incontinence.
* Individual has at least one urgency urinary incontinence episode on each of three days as determined on a 3-day voiding diary.
* Individual gives written informed consent.
* Individual is mentally competent and able to understand all study requirements.
* Individual is willing and able to complete a 3-day voiding diary and quality of life questionnaire.
* Individual is without pharmacological treatment of overactive bladder (anticholinergic and β3-adrenoceptor agonists) for 2 weeks prior to baseline or longer if the physician judges that the therapeutic effect is still present.
* Individual is intolerant of or has an inadequate response to any of anticholinergics, β3-adrenoceptor agonists, onabotulinumtoxinA, or who have undergone percutaneous tibial nerve stimulation (PTNS).
* Individual is determined to be a suitable surgical candidate by physician.
* Individual is appropriate for eCoin treatment based on the US FDA-approved IFU requirements.

Exclusion Criteria:

* Individual is not appropriate for eCoin therapy based upon the US FDA-approved IFU requirements.
* Individual has clinically significant bladder outlet obstruction. (Suspected bladder outlet obstruction will be initially assessed by uroflow study with those having a maximum flow rate \< 15mL/s requiring additional evaluation.)
* Individual has predominantly stress urinary incontinence (greater than 1/3 of leaks on baseline diary are stress).
* Individual has an active urinary tract infection at time of enrollment.
* Individual has known polyuria.
* Individual has significant lower urinary tract pain or has been diagnosed with interstitial cystitis or bladder pain syndrome.
* Individual has abnormal post void residual (i.e. greater than 200 cc initially and on repeat testing after double voiding)
* Individual has clinically significant urethral stricture disease or bladder neck contracture. (Suspected disease or contracture will be initially assessed by uroflow study with those having a maximum flow rate \< 15mL/s requiring additional evaluation.)
* Individual has chronic venous insufficiency with a history of skin change (hyperpigmentation, lipodermatosclerosis, ulceration) in the ankle region.
* Individual has morbid obesity and in the opinion of the investigator is not a good candidate for the study.
* Individual has had diagnosis of bladder, urethral, or prostate cancer.
* Individual has had a prior anti-stress incontinence sling surgery within the last year.
* Individual is pregnant or intends to become pregnant during the study.
* Individual has the presence of urinary fistula, bladder stone, or interstitial cystitis.
* Individual has uncontrolled diabetes mellitus (Hemoglobin A1C\>7) or diabetes with significant peripheral complications. (Uncontrolled diabetes will be ruled out by blood test excluding those with Hemoglobin A1C\>7).
* Individual has an implantable neurostimulator, pacemaker, or implantable cardiac defibrillator (ICD).
* Individual has been treated with onabotulinumtoxinA in the previous 9 months prior to enrollment, or more time if the principal investigator judges that the therapeutic effect is present.
* Individual has been treated with percutaneous tibial nerve stimulation (PTNS) within the previous 4 weeks prior to enrollment or more time if the principal investigator judges that the therapeutic effect is present.
* Individual is currently using transcutaneous electrical nerve stimulation (TENS) in the pelvic region, back, or legs.
* Individual is aware that he or she will need an MRI scan other than a head/neck/shoulder MRI during the study period.
* Individual has a clotting or bleeding disorder or is using anticoagulant therapies and in the opinion of the investigator is not a good candidate for the study (antiplatelet and anticoagulant therapy may be continued or held at the discretion of the investigator).
* Individual is neutropenic or immune-compromised.
* Individual has had previous surgery and/or significant scarring at the implant location.
* Individual has ongoing dermatologic condition at the implant site, including but not limited to dermatitis and autoimmune disorders.
* Individual has a clinically significant peripheral neuropathy in the lower extremities.
* Individual has neurogenic bladder dysfunction.
* Individual has pitting edema at implant location (≥ 2+ is excluded).
* Individual has inadequate skin integrity or any evidence of an infection or inflammation in either lower leg.
* Individual has varicose veins and is symptomatic.
* Individual has open wounds, trauma, or prior surgery in the lower extremities.
* Individual has arterial disease in the lower extremities.
* Individual has vasculitis in the lower extremities.
* Individual has bladder stones or neoplasia. (Suspected bladder stones or neoplasia will be ruled out with a urine dipstick showing no more than trace blood, and microscopic analysis (which should be done in that case) shows ≥3 PBC's /HPF unless that subject has been worked up and found negative for clinically significant disease such as malignant neoplasm or stones.)
* In the opinion of the investigator, Individual is not a good candidate for participation in the study.

Where this trial is running

Homewood, Alabama and 21 other locations

Study contacts

How to participate

  1. Review the eligibility criteria above with your treating physician.
  2. Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
  3. Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.
View on ClinicalTrials.gov → Find more trials like this →
Conditions Overactive BladderUrge IncontinenceIncontinence, UrinaryUrinary Urge Incontinence
Last reviewed 2026-06-13 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.